Expertise in
25
conditions

Dr. Alexander Colevas

Oncology
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
25
conditions
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 

Overview

Alexander Colevas is an Oncologist in Palo Alto, California. Dr. Colevas is highly rated in 25 conditions, according to our data. His top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Squamous Cell Carcinoma, and Thyroid Cancer.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MD

Hospital Affiliations

Stanford Health Care Tri-Valley
Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304
Other Locations
Tanya W Spirtos MD Wommens Cancer
900 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: CUE-101, Pembrolizumab
Study Phase: Phase 1
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drug: VK-2019
Study Phase: Phase 2
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Enrollment Status: Completed
Publish Date: March 27, 2025
Intervention Type: Drug, Biological
Study Drugs: Gedeptin, Fludarabine
Study Phase: Phase 1/Phase 2
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Enrollment Status: Terminated
Publish Date: August 15, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin, Cetuximab
Study Phase: Phase 1
A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients With Advanced Nasopharyngeal Carcinoma (NPC)
A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients With Advanced Nasopharyngeal Carcinoma (NPC)
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 11 Less Clinical Trials

143 Total Publications

Mitochondrial Imaging Detects Early Cardiac Responses to Cancer Immunotherapy.
Mitochondrial Imaging Detects Early Cardiac Responses to Cancer Immunotherapy.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology
Expertise in
22
conditions
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Khodadoust is an Oncologist and a Hematologist in Stanford, California. Dr. Khodadoust is highly rated in 22 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Allison W. Kurian
Expertise in
26
conditions
Dr. Allison W. Kurian
Oncology | Hematology Oncology | Hematology
Expertise in
26
conditions
Dr. Allison W. Kurian
Oncology | Hematology Oncology | Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Kurian is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Kurian is highly rated in 26 conditions, according to our data. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Inflammatory Breast Cancer, Li-Fraumeni Syndrome, and Salpingo-Oophorectomy.

Expertise in
11
conditions
Dr. Lipika C. Goyal
Oncology | Hematology Oncology
Expertise in
11
conditions
Dr. Lipika C. Goyal
Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lipika Goyal is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Goyal is highly rated in 11 conditions, according to our data. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Fibrolamellar Carcinoma, Tissue Biopsy, and Pancreaticoduodenectomy.

Frequently Asked Questions about Dr. Alexander Colevas

How do I make an appointment with Dr. Alexander Colevas?

You can book an appointment with Dr. Alexander Colevas by calling their office at 650-498-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alexander Colevas a top-rated expert for Nasopharyngeal Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alexander Colevas is classified as an Elite expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alexander Colevas specialize in?

While Dr. Alexander Colevas is a Oncology, they have specific expertise in Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Oral Squamous Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Alexander Colevas participate in research or clinical trials?

Yes. Dr. Alexander Colevas has published 143 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Dr. Alexander Colevas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alexander Colevas accept my insurance?

Dr. Alexander Colevas accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 650-498-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colevas's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 15 Advanced Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile